Orforglipron 与甘精胰岛素在心血管风险升高的 2 型糖尿病成人中的心血管安全性(ACHIEVE-4):一项 3 期、事件驱动、随机、开放标签、非劣效性、阳性对照试验
ACHIEVE-4 是一项在 16 个国家和地区 317 个中心开展的 3 期、事件驱动、随机、开放标签、阳性对照、非劣效性试验,纳入心血管风险升高且合并已确诊心血管或慢性肾脏病的 2 型糖尿病成人(HbA1c 7.0%-10.5%,BMI≥25 kg/m2),随机接受口服 Orforglipron 最大耐受剂量(最高 36 mg 胶囊)或皮下滴定甘精胰岛素,每日一次。中位随访 2 年,主要终点 MACE-4 在 Orforglipron 组发生 57/1358 例(4.2%)、甘精胰岛素组 67/1343 例(5.0%),HR 0.84(95%CI 0.59-1.20),非劣效性 P<0.0001。Orforglipron 组胃肠道不良事件 851/1371 例(62.1%)高于甘精胰岛素组 193/1355 例(14.2%),有临床意义的严重低血糖 93/1371 例(6.8%)低于甘精胰岛素组 260/1355 例(19.2%)。作者认为这些结果支持 Orforglipron 作为每日一次口服、具有已确立心血管安全性的潜在治疗选择。
要点
- 在心血管风险升高的 2 型糖尿病成人中,Orforglipron 对比甘精胰岛素对 MACE-4 达到非劣效:HR 0.84(95%CI 0.59-1.20),非劣效性 P<0.0001。
- 中位随访 2 年,MACE-4 在 Orforglipron 组发生 57/1358 例(4.2%),甘精胰岛素组 67/1343 例(5.0%)。
- 有临床意义的严重低血糖(血糖<3 mmol/L [54 mg/dL])Orforglipron 组 93/1371 例(6.8%),低于甘精胰岛素组 260/1355 例(19.2%)。
- 胃肠道不良事件 Orforglipron 组 851/1371 例(62.1%),高于甘精胰岛素组 193/1355 例(14.2%),是 Orforglipron 最常见的停药原因。
- 研究期间死亡 62 例:Orforglipron 组 19/1371 例(1.4%),甘精胰岛素组 43/1355 例(3.2%);除甘精胰岛素组 1 例外,均判定与治疗无关。
适用人群与场景
- 心血管风险升高且合并已确诊心血管疾病或慢性肾脏病的 2 型糖尿病成人,HbA1c 7.0%-10.5%(53-91 mmol/mol),BMI≥25 kg/m2,正在使用至多三种降糖药(二甲双胍、磺脲类和/或 SGLT2 抑制剂)。
- 研究在 16 个国家和地区 317 个中心开展;共 2749 例随机(Orforglipron 组 1371 例,甘精胰岛素组 1378 例),女性 1032 例(38%),男性 1717 例(62.5%),已确诊心血管疾病 2362 例(85.9%),慢性肾脏病 1033 例(37.6%),基线平均年龄 63.1 岁(SD 9.9),平均 HbA1c 8.2%(1.0),平均 BMI 33 kg/m2(6.2)。
处置流程与药物剂量
- Orforglipron 组:口服 Orforglipron 最大耐受剂量(最高 36 mg 胶囊 [相当于 17.2 mg 片剂]),每日一次。
- 甘精胰岛素组:皮下注射滴定甘精胰岛素,每日一次。
研究设计与关键结果
- 研究类型:3 期、事件驱动、多中心、随机、开放标签、阳性对照、平行组、非劣效性试验;2749 例随机,中位随访 2 年。
- 主要终点 MACE-4(心血管死亡、非致死性心肌梗死、非致死性卒中或不安定型心绞痛住院)在 Orforglipron 组发生 57/1358 例(4.2%),甘精胰岛素组 67/1343 例(5.0%),HR 0.84(95%CI 0.59-1.20),非劣效性 P<0.0001(非劣效界值为 HR 95%CI 上限<1.8)。
- 胃肠道不良事件:Orforglipron 组 851/1371 例(62.1%),甘精胰岛素组 193/1355 例(14.2%)。
- 有临床意义的严重低血糖(血糖<3 mmol/L [54 mg/dL]):Orforglipron 组 93/1371 例(6.8%),甘精胰岛素组 260/1355 例(19.2%)。
- 死亡:研究期间共 62 例,Orforglipron 组 19/1371 例(1.4%),甘精胰岛素组 43/1355 例(3.2%);除甘精胰岛素组 1 例外,均判定与治疗无关。
证据类型、等级与局限
- 证据类型:3 期、事件驱动、随机、开放标签、阳性对照、非劣效性试验。
- 作者结论:在心血管风险升高的 2 型糖尿病成人中,Orforglipron 对比甘精胰岛素对 MACE-4 达到非劣效,证实其心血管安全性;胃肠道不良事件是最常见不良事件及 Orforglipron 最常见停药原因,有临床意义的低血糖 Orforglipron 少于甘精胰岛素;作者认为这些发现支持 Orforglipron 作为每日一次口服、具有已确立心血管安全性的潜在治疗选择。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于心血管风险升高且合并已确诊心血管疾病或慢性肾脏病的 2 型糖尿病成人,Orforglipron 对 MACE-4 不劣于甘精胰岛素,可减少有临床意义的严重低血糖,但胃肠道不良事件更常见且是 Orforglipron 最常见停药原因。
- 作者认为 Orforglipron 可作为每日一次口服、具有已确立心血管安全性的潜在治疗选择。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Orforglipron is an oral, non-peptide GLP-1 receptor agonist. While some peptide GLP-1 receptor agonists have established cardiovascular benefit, the cardiovascular safety of non-peptide GLP-1 receptor agonists has not been studied. This study aimed to compare the effect of orforglipron with insulin glargine on the incidence of major adverse cardiovascular events in individuals with type 2 diabetes and obesity or overweight who are at increased risk for cardiovascular events.
METHODS: This event-driven, phase 3, multicentre, randomised, open-label, active comparator, parallel-group study was conducted in 317 sites across 16 countries and territories. Adults with type 2 diabetes at increased cardiovascular risk with glycated haemoglobin (HbA1c) concentrations between 7·0% and 10·5% (53-91 mmol/mol) and a BMI of 25 kg/m2 or more, treated with up to three glucose-lowering medications (metformin, a sulfonylurea, and/or an SGLT2 inhibitor), were randomly assigned (1:1) to oral orforglipron maximum tolerated dose (up to 36 mg capsule [equivalent to 17·2 mg tablet]) or injectable titrated insulin glargine, each administered once daily. All participants had established cardiovascular or chronic kidney disease. The primary outcome was time to occurrence of four-component major adverse cardiovascular events (MACE-4), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or hospitalisation for unstable angina. Non-inferiority of orforglipron to insulin glargine was declared if the upper limit of the two-sided 95% CI for the hazard ratio (HR; orforglipron vs insulin glargine) was less than 1·8. The primary endpoint and other safety endpoints were assessed in all participants who took at least one dose of assigned treatment using all datapoints from baseline until withdrawal or study completion, regardless of treatment adherence. This trial was registered on ClinicalTrials.gov (NCT05803421) and is completed.
FINDINGS: Between May 1, 2023, and Sept 5, 2024, 2749 participants were randomly assigned (1371 to orforglipron and 1378 to insulin glargine). 1032 (38%) participants were female and 1717 (62·5%) male. 2362 (85·9%) participants had established cardiovascular disease and 1033 (37·6%) had chronic kidney disease. Mean baseline age, HbA1c, and BMI were 63·1 years (SD 9·9), 8·2% (1·0), and 33 kg/m2 (6·2), respectively. Over a median follow-up of 2 years, the primary outcome occurred in 57 (4·2%) of 1358 orforglipron participants and 67 (5·0%) of 1343 insulin glargine participants, showing non-inferiority to insulin glargine for MACE-4 (HR 0·84; 95% CI 0·59-1·20; p<0·0001 for non-inferiority). Gastrointestinal adverse events were reported in 851 (62·1%) of 1371 orforglipron participants and 193 (14·2%) of 1355 insulin glargine participants; clinically significant or severe hypoglycaemia (glucose <3 mmol/L [54 mg/dL]) occurred in 93 (6·8%) of 1371 orforglipron participants and 260 (19·2%) of 1355 insulin glargine participants. 62 deaths were reported during the study: 19 (1·4%) of 1371 participants receiving orforglipron and 43 (3·2%) of 1355 participants receiving insulin glargine; all deaths except one (in the insulin glargine group) were deemed unrelated to treatment.
INTERPRETATION: In people with type 2 diabetes at increased cardiovascular risk, the cardiovascular safety of orforglipron was confirmed by demonstrating non-inferiority to insulin glargine for MACE-4. Gastrointestinal adverse events were the most frequent adverse event and most common reason for orforglipron treatment discontinuation with orforglipron, while clinically significant hypoglycaemia occurred less frequently with orforglipron than with insulin glargine. These findings support orforglipron as a potential once-daily, oral treatment option with established cardiovascular safety in people with type 2 diabetes and increased cardiovascular risk.
FUNDING: Eli Lilly and Company.
参考来源
- Klein KR, Wysham C, Tuttle KR, et al. Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. Lancet. 2026. PMID: 42815506. doi:10.1016/S0140-6736(26)01865-9
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。